Last reviewed · How we verify
Tamsulosin BID
Tamsulosin is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow.
Tamsulosin is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow. Used for Benign prostatic hyperplasia with lower urinary tract symptoms.
At a glance
| Generic name | Tamsulosin BID |
|---|---|
| Sponsor | Gundersen Lutheran Medical Foundation |
| Drug class | Alpha-1A adrenergic receptor antagonist |
| Target | Alpha-1A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Tamsulosin selectively blocks alpha-1A adrenergic receptors located on smooth muscle cells in the prostate gland and bladder neck. By antagonizing these receptors, it reduces smooth muscle tone and tension in these tissues, thereby decreasing urinary obstruction and improving urinary symptoms associated with benign prostatic hyperplasia. The BID (twice daily) formulation indicates dosing twice per day, though extended-release once-daily formulations are more common.
Approved indications
- Benign prostatic hyperplasia with lower urinary tract symptoms
Common side effects
- Retrograde ejaculation
- Dizziness
- Headache
- Asthenia/fatigue
- Orthostatic hypotension
- Rhinitis
Key clinical trials
- Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Pain in the Pediatric Population (NA)
- The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH (PHASE4)
- Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter (PHASE3)
- Medications for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (PHASE3)
- Comparing the Efficiency of Two Approaches in Patients at Risk of Developing Intraoperative Floppy Iris Syndrome (PHASE4)
- Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms: (NA)
- The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia (PHASE4)
- Orthostatic Hypotension Treatment on Rehab Unit (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tamsulosin BID CI brief — competitive landscape report
- Tamsulosin BID updates RSS · CI watch RSS
- Gundersen Lutheran Medical Foundation portfolio CI